1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Sartorius AG

Sartorius AG

SSSGY
Sartorius AGUS flagOther OTC
43.93
USD
- -
- -
15.17BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.32
2.61
3.27
3.8
4.11
4.58
5.34
6.83
10.08
12.2
9.93
9.8
10.25
7.83
Basic EPS, GAAP
0.15
0.14
0.37
0.3
0.34
0.41
0.46
0.61
0.93
1.98
0.6
0.24
0.45
0.53
Free Cash Flow per Basic Share
0.3
0.38
0.37
0.5
0.6
0.72
1.1
1.5
2.55
2.15
0.86
1.64
1.14
1.05
Dividend per Share
0.05
0.05
0.07
0.08
0.09
0.1
0.12
0.07
0.14
0.25
0.29
0.15
0.15
0.15
Book Value per Share
0.05
0.05
0.05
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
Tangible Book Value per Share
-0.29
-0.16
0.09
- -
-0.8
-0.26
-0.1
-2.46
-2.16
-1
-8.03
-4.56
-4.14
-4.04
Basic Weighted Avg Shares
341
341
341
342
342
342
342
342
342
342
342
345
345
346
Sales/Revenue/Turnover
792
891
1,115
1,300
1,405
1,566
1,827
2,336
3,449
4,175
3,396
3,381
3,538
2,711
Operating Margin (%)
14.65
14.6
18.99
19.05
18.72
19.2
19.89
21.89
27.06
27.29
16.02
12.93
16.09
16.82
Depreciation Expense
48
55
59
76
98
113
133
180
231
287
342
416
420
320
Net Income, GAAP
52
48
126
103
115
141
157
210
319
678
206
84
155
182
Effective Tax Rate (%)
30.71
33.65
31.9
28.96
20.81
27.05
27.85
29.47
36.12
22.73
24.85
26.45
31.6
32.89
Profit Margin (%)
6.62
5.44
11.33
7.92
8.17
9.03
8.58
9
9.25
16.24
6.05
2.48
4.38
6.71
Working Capital
146
187
206
223
278
273
188
338
250
220
627
669
-201
-190
LT Debt
369
379
366
452
887
895
881
1,892
1,738
1,986
5,023
4,167
3,356
3,337
Total Equity
450
498
645
737
807
973
1,093
1,380
1,720
2,659
2,758
3,898
3,867
3,891
Return on Invested Capital (%)
9.79
9.67
14.47
14.64
13.26
11.37
12.23
12.36
15.65
18.53
5.93
3.79
4.59
3.63
Return on Capital (%)
9.1
7.47
19.27
10.29
8.23
7.61
7.8
6.95
8.93
15.99
4.91
2.81
3.52
4.58
Return on Common Equity (%)
307.53
284.47
739.83
240.82
167.76
206.68
229.12
307.15
466.17
991.37
300.58
122.27
224.33
263.43

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
926
964
LT Borrowings
- -
3,184
3,169
LT Finance Leases
- -
172
168
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
69
69
69
Market Capitalization
11,170
12,767
12,596

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
1,766
1,923
Cash, Cash Equivalents & STI
- -
552
600
Accounts Receivable, Net
- -
225
304
Inventories
- -
792
827
Total Current Liabilities
- -
1,967
2,113
Payables & Accruals
- -
- -
- -
ST Debt
- -
926
964
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.65%
24.7%
-0.78%
Free Cash Flow
22.27%
11.45%
-30.23%
Net Income, GAAP
18.11%
24%
84.4%
Sales/Revenue/Turnover
13.49%
10.85%
4.66%
Total Cash Common Dividend
16.23%
28.58%
0.2%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
820
861
794
907
3,381
2025
883
884
- -
928
3,538
2026
899
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.11
0.07
0.02
- -
0.24
2025
0.14
0.09
- -
- -
0.45
2026
0.16
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.15
2025
- -
- -
- -
- -
0.15
2026
0.15
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Michael Grosse
Full Time Employees
14,242
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Address
Otto-Brenner-Strasse 20 Göttingen NI Germany 37079
IPO Date
Jan 19, 2021
Website
sartorius.com
Similar Companies
BG Medicine, Inc. (BGMD)
ICU Medical, Inc. (ICUI)
Bioteque Corporation (4107.TWO)
Sector 10, Inc. (SECI)
Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SS)
Avinger, Inc. (AVGR)
Business
Sartorius AG, a leading international partner of life science research and the biopharmaceutical industry, develops, manufactures and markets innovative laboratory instruments, consumables and bioprocess solutions. The company operates through two main divisions: Bioprocess Solutions, which provides single-use bioreactors, fermenters, membrane chromatography devices, filtration systems, cell line and process development services including the CHO Expression Platform, manufacturing process platforms and modular facility elements to support the production of biotech medications, vaccines and cell and gene therapies; and Lab Products & Services, which supplies high-precision laboratory balances, pipettes, water purification systems, lab consumables, cell analysis instruments, reagents, bioanalytics tools and 3D cell-based microtissues for research, quality control and drug development in pharmaceutical, biopharmaceutical, chemical and food industries. Founded in 1870 and headquartered in Goettingen, Germany, Sartorius maintains a global presence with approximately 60 production and sales sites across the Americas, EMEA, Asia|Pacific regions, employing around 13,900 people and serving customers from academic institutes to major biopharma producers. In recent developments, Sartorius completed the acquisition of MatTek Corp, including Visikol Inc, on July 1, 2025, integrating advanced human cell-based 3D models into its Lab Products & Services division to enhance drug development capabilities and synergies with cell analysis tools; formed partnerships in 2025 with Nanotein Technologies for cell therapy reagents, Sensible and Tulip Interfaces for process automation including integration with its Biobrain suite; and launched new filtration solutions for monoclonal antibodies, bioprocess software and weighing technology advancements, while reporting 7.5 percent sales revenue growth to 2.61 billion euros in the first nine months of 2025 driven by consumables.